Walgreens Boots Alliance Inc

Walgreens Boots Alliance — Q2 2023 Earnings Presentation

37 slides from Walgreens Boots Alliance's earnings presentation, Mar 28, 2023

  1. Slide 1: Reimagining Local Healthcare and Wellbeing for All

    Reimagining Local Healthcare and Wellbeing for All Second Quarter Fiscal 2023 Results March 28, 2023 © 2023 Walgreens Boots Alliance, Inc. All rights reserved.

  2. Slide 2: Safe Harbor and Non-GAAP

    Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat

  3. Slide 3: Building momentum and accelerating our healthcare transformation

    Building momentum and accelerating our healthcare transformation • Solid 2Q performance in line with expectations, with acceleration in February • Resilient core business with U.S. script volume growth ahead of 2Q guidance and healthy U.S. retail and Boots UK retail trends on top of strong prior yea

  4. Slide 4: Continued rapid progress across our four strategic priorities

    Continued rapid progress across our four strategic priorities • U.S. pharmacy comp scripts ex. immunizations +3.5%, improving vs. +2.1% in 1Q • U.S. retail comp sales ex. tobacco (0.5)% on top of +15.7% last year, a 2-year stack of +15.2% Transform and align the core • Walgreens administered 2.4 mil

  5. Slide 5: Leading healthcare assets delivering value across the care continuum

    Leading healthcare assets delivering value across the care continuum Primary & Wellness & prevention Pre-acute multi-specialty care Specialty care Post-acute Retail Pharmacy Health Corners Retail pharmacy services, Pharmacist-led chronic Value-based primary care Specialty care and Post-acute care se

  6. Slide 6: 2Q 2023 financial highlights

    2Q 2023 financial highlights • 2Q 2023 adj. EPS of $1.16 vs. prior year adj. EPS of $1.59, down 25.8% on a constant currency basis − Lapping strong growth of 26.5% in the year-ago quarter which was boosted by COVID-19 vaccines and testing − 26% headwind from lower contributions from COVID-19 vaccine

  7. Slide 7: WBA 2Q23 Financial Highlights

    Reported Fx Constant Fx 2Q23 $ in millions (except EPS) B/(W) vs. 2Q22 B/(W) vs. 2Q22 Sales $34,862 + 3.3% + 4.5% Operating Income GAAP $197 ($1,049) WBA 2Q23 Adjusted $1,215 (26.7)% (25.4)% Financial Highlights Net Earnings GAAP $703 (20.4)% Adjusted $1,000 (27.4)% (26.0)% EPS GAAP $0.81 (20.3)% Ad

  8. Slide 8: WBA 1H23 Financial Highlights

    Reported Fx Constant Fx 1H23 $ in millions (except EPS) B/(W) vs. 1H22 B/(W) vs. 1H22 Sales $68,244 + 0.9% + 2.8% Operating Income GAAP ($5,954) ($8,483) WBA 1H23 Adjusted $2,229 (35.1)% (34.1)% Financial Net Earnings GAAP ($3,018) ($7,481) Highlights Adjusted $2,004 (29.2)% (28.1)% EPS GAAP ($3.50)

  9. Slide 9: U.S. Retail Pharmacy Financials

    2Q23 B/(W) vs. 2Q22 1H23 B/(W) vs. 1H22 $ in millions Sales $27,577 (0.3)% $54,781 (1.6)% Adj. gross profit $5,850 (9.8)% $11,760 (8.5)% Adj. SG&A % of sales 17.7% + 0.5%p 17.9% (0.2)%p U.S. Retail Adj. operating income $1,067 (32.8)% $2,172 (33.7)% Pharmacy Adj. operating margin1 3.5% (1.7)%p 3.5%

  10. Slide 10: U.S. Pharmacy

    2Q23 2Q23 1H23 1H23 2Q23 vs. 2Q22 | 1H23 vs. 1H22 Total Comparable Total Comparable Pharmacy sales + 0.3% + 4.9% (2.0)% + 4.9% Prescriptions (0.7)% + 0.2% (0.7)% + 0.1% Prescriptions ex. +2.7% + 3.5% +2.0% + 2.8% Immunizations U.S. Pharmacy • Comp sales +4.9% with growth primarily due to brand infla

  11. Slide 11: U.S. Retail

    2Q23 1H23 2Q23 vs. 2Q22 | 1H23 vs. 1H22 Total retail sales (1.8)% (0.6)% Comparable retail sales (1.0)% + 0.1% • Comp ex. tobacco (0.5)%, lapping a record quarter with comp sales of +15.7% U.S. Retail − 500 bps headwind from lower sales of OTC test kits − Excluding OTC test kits, +4.5% comp reflects

  12. Slide 12: International Financials

    Constant Fx Constant Fx 2Q23 1H23 $ in millions B/(W) vs. 2Q22 B/(W) vs. 1H22 Sales $5,651 + 9.0% $10,840 + 6.8% Adj. gross profit $1,198 + 7.5% $2,248 + 4.8% Adj. SG&A % of sales 15.0% + 2.4%p 16.4% + 1.1%p International Adj. operating income $352 + 65.7% $468 + 29.6% Financials Adj. operating marg

  13. Slide 13: Boots UK Financials

    2Q23 1H23 2Q23 vs. 2Q22 | 1H23 vs. 1H22 (constant Fx) Pharmacy comp. sales + 2.0% + 0.5% Retail comp. sales + 16.0% + 12.4% Boots UK • Pharmacy comp sales +2.0% held back by lower demand for COVID-19 services Financials • Retail comp sales accelerated to +16% in 2Q − Store footfall improved +16% vs.

  14. Slide 14: U.S. Healthcare Financials

    2Q23 B/(W) vs. 2Q22 1H23 B/(W) vs. 1H22 $ in millions Sales $1,634 + $1,107 $2,622 + $2,045 Adj. gross profit $110 + $95 $153 + $118 Adj. SG&A ($269) ($177) ($464) ($339) U.S. Healthcare Adj. operating loss ($159) ($82) ($311) ($221) Financials Adj. EBITDA ($109) ($48) ($233) ($161) • U.S. Healthcar

  15. Slide 15: U.S. Healthcare Key Metrics

    Current Status1 Organic Contracted Lives2 2.9M Organic Partners (Payor/Provider)2 4 VillageMD/Summit Health Value-Based Lives3 806K Sites of Care: Health Corners 117 VillageMD Co-Located Clinics 210 U.S. Healthcare Total VillageMD/Summit/CityMD Locations 729 Key Metrics Pro Forma YOY $ millions 2Q23

  16. Slide 16: Cash Flow

    B/(W) 1H23 $ in millions vs. 1H22 Operating cash flow $1,239 ($945) Cash capital expenditure ($1,108) ($238) Free cash flow1 $560 ($754) Cash Flow • YTD cash generation of $1.2 billion in operating cash flow and $560 million of free cash flow • Year-over-year free cash flow adversely impacted by low

  17. Slide 17: WBA FY23 Outlook

    Confirming adj. EPS guidance, pivoting to strong 2H growth • Solid start to the year with 1H results in line with expectations • Resilient core retail pharmacy business successfully lapping record prior year performances • Good visibility into drivers of robust and accelerating 2H growth WBA FY23 −

  18. Slide 18: Building momentum and accelerating our healthcare transformation

    Building momentum and accelerating our healthcare transformation • Solid 2Q performance in line with expectations, with acceleration in February • Resilient core business with U.S. script volume growth ahead of 2Q guidance and healthy U.S. retail and Boots UK retail trends on top of strong prior yea

  19. Slide 19: Q&A

    Q&A © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 19

  20. Slide 20: Endnotes

    Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures. • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating

  21. Slide 21: Appendix

    Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente

  22. Slide 22: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,

  23. Slide 23: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING LOSS, ADJUSTED EBITDA and ADJUSTED EBITDAR As Reported Twelve months ended February 28, 2023 Net loss (GAAP) $ (3,544) Post-

  24. Slide 24: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa

  25. Slide 25: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET EARNINGS (LOSS) Three months ended February 28, Change vs. 2Q22 Six months ended February 28, Change vs. 1H22 2023 2022 Amoun

  26. Slide 26: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET EARNINGS (LOSS) Three months ended February 28, Change vs. 2Q22 Six months ended February 28, Change vs. 1H22 2023 2022 Amoun

  27. Slide 27: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa

  28. Slide 28: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,577

  29. Slide 29: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2022 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,667

  30. Slide 30: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2023 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 54,781 $

  31. Slide 31: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2022 Walgreens Boots U.S. Retail Pharmacy1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 55,699 $

  32. Slide 32: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income (loss) for U.S. Retail Pharmacy includes equity earnings in AmerisourceBergen. As a result of the two-month reporting lag, operating income (loss) for

  33. Slide 33: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR U.S. HEALTHCARE SEGMENT Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Operating l

  34. Slide 34: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN AMERISOURCEBERGEN Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Equity earnings in AmerisourceBergen

  35. Slide 35: Reconciliation of Non-GAAP financial measures

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended February 28, 2023 Three months ended February 28, 2022 Earnings before Earnings before income tax Income tax

  36. Slide 36: Free Cash Flow

    Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Net cash provided by operating activities (GAAP) $ 745 $ 1

  37. Slide 37: Supplemental Financial Information

    Supplemental Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Supplemental sale and leaseback financial information (unaudited) Three months ended Six months ended February 28, 2023 Change vs. 2Q22 February 28, 2023 Change vs. 1

Walgreens Boots Alliance — Q2 2023 Earnings Presentation on 6ix